The DOI matches its Crossref record; 349 of the 363 references it cites were found in a registry or an index; 20 of the 40 sources its claims cite were checked for support.
Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.
Open accessAbstract
Updated ISHLT consensus providing a framework for identifying candidates for lung transplantation and accounting for combinations of risk factors in candidacy selection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
9 Partly supported · 6 No basis given · 4 Couldn’t confirm · 3 Own method · 1 Supported · 1 Sources not found · 1 No full text of the sources · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The ESC/ERS model also employs the assessment of risk using a multi-parametric comprehensive analysis of clinical variables.(284) Unlike REVEAL, this model avoids use of any non-modifiable criteria, and does not “weight” the variables according to their relative importance.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > PULMONARY ARTERIAL HYPERTENSION (PAH)
What the sources say
- Partly supportedcites [284] Galiè, 2016, Eur Heart J sourceExperimental — accuracy not yet measured
Section 6.2.4 calls for a multidimensional, comprehensive assessment, and section 6.2.5 says overall assessment should guide decisions when variables fall into different risk categories. The claim that the model avoids any nonmodifiable criteria is too absolute: both sections say age, sex, and other factors not affected by therapy can modify risk. The passages do not explicitly specify whether variables receive numerical weights. (LLM, conf=0.85)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This trend reflects the expansion of acceptable donors and candidates made possible by clinical and scientific advances. Far fewer absolute contraindications for lung transplant candidacy exist now, compared to the time of publication of prior versions of this document, making the selection of candidates even more complex.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > INTRODUCTION:
What the sources say
- Partly supportedcites [2] Orens, 2006, International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The introduction says advances in technology and medical knowledge prompted updated candidate-selection guidelines, and the Relative contraindications section allows consideration of some candidates previously treated more restrictively. But our copy does not state that lung transplantation expanded worldwide because more donors became acceptable, nor does it explicitly say there are far fewer absolute contraindications than in 1998 or that selection has become more complex for that reason. No page numbers are available in our copy. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [3] Maurer, 1998, International guidelines for the selection of lung transplant candidates, Transplantation source
- Not checked — no full text of the sourcecites [4] Weill, 2015, A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant source
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Frailty, defined as a generalized vulnerability to stressors resulting from the presence of multiple physiologic deficits, is associated with an increased risk of waitlist and post-transplant mortality.(51–53) However, frailty in lung transplant candidates is often attributable to advanced lung disease and may improve following transplant.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > RISK FACTORS TO BE CONSIDERED: > Functional Status and Frailty:
What the sources say
- Partly supportedcites [51] Baldwin, 2017, Refining low physical activity measurement improves frailty assessment in advanced lung disease and survivors of critical illness, Ann Am Thorac Soc sourceExperimental — accuracy not yet measured
The Results (page unavailable) link frailty measured with FFP-DASI to increased death or delisting among lung-transplant candidates. The Methods (page unavailable) say participants were censored at transplant, so this study does not support the post-transplant mortality claim. The Abstract says no gold-standard frailty measure exists, but the paper does not specifically address using frailty measures for listing decisions. (LLM, conf=0.90)
- Supportedcites [52] Singer, 2018, Frailty phenotypes and mortality after lung transplantation: a prospective cohort study, Am J Transplant source
The Discussion states that frailty is associated with both waitlist and post-transplant mortality. It also says further work is needed to identify valid frailty measures before using them in organ allocation; the available passages do not give page numbers. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [53] Singer, 2015, Frailty phenotypes, disability, and outcomes in adult candidates for lung transplantation, Am J Respir Crit Care Med source
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Despite improved overall outcomes, many individuals with advanced CF lung disease remain at risk of short-term mortality. A 2017 study demonstrated a 10% risk of death each year after reaching an FEV1 < 30%, with many patients dying soon after reaching this threshold.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CYSTIC FIBROSIS
What the sources say
- Supportedcites [245] Ramos, 2017, Heterogeneity in survival in adult patients with cystic fibrosis with FEV1 < 30% of predicted in the United States, Chest source
The Discussion reports improved survival but an approximately 10% annual probability of death once FEV1 falls below 30% predicted. The Conclusions add that some patients die soon after reaching that threshold, while others live for many years. (LLM, conf=0.92)
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung transplant candidates must demonstrate abstinence from use of all tobacco and nicotine products (including nicotine replacement therapy) prior to transplant (e.g. with serial nicotine and cotinine screening).(111)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > PSYCHOSOCIAL RISK FACTORS: > Nicotine:
What the sources say
- Partly supportedcites [111] Hofmann, 2018, Smoking resumption after heart or lung transplantation: a systematic review and suggestions for screening and management, J Thorac Dis sourceExperimental — accuracy not yet measured
The Introduction says candidates are normally required to be smoke-free before joining a thoracic-transplant waiting list. But the systematic-screening section recommends cotinine testing at post-transplant follow-ups, not serial nicotine and cotinine testing before transplant. The paper also says nicotine replacement therapy can be used in transplant recipients; it does not establish the claimed pre-transplant ban on all nicotine products. (LLM, conf=0.88)
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Non-CF bronchiectasis represents 2.7% of all lung transplants reported to the ISHLT Registry between 1995–2018.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > NON-CYSTIC FIBROSIS BRONCHIECTASIS
What the sources say
- Could not verifycites [1] Chambers, 2019, The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: donor and recipient size match, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Lung transplantation—Indications section says Table 1 covers transplant indications since January 1995, but the passages available from our copy do not give a figure for non-CF bronchiectasis. Searches for “non-CF bronchiectasis,” “bronchiectasis,” and “2.7%” did not find the claimed proportion; the quoted passages instead discuss other indications and bronchiolitis obliterans syndrome. (LLM, conf=0.70)
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung transplant for LAM is relatively rare; however, it is associated with better post-transplant survival compared to other advanced lung diseases.(1, 303–307)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > LYMPHANGIOLEIOMYOMATOSIS (LAM)
What the sources say
- Partly supportedcites [1] Chambers, 2019, The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: donor and recipient size match, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Lung transplantation section (page unavailable) reports that lymphangioleiomyomatosis as an indication for transplantation is favorably associated with survival in a multivariable model. It does not establish that LAM transplantation is relatively rare or recommend bilateral transplantation when organs are available; its favorable association for bilateral transplantation is reported separately, not specifically for LAM. (LLM, conf=0.87)
- Supportedcites [303] Ando, 2016, Lung Transplantation for lymphangioleiomyomatosis in Japan, PLoS One source
The Introduction describes LAM as rare and says it accounted for about 1% of heart or lung transplantation indications in an international survey. The Discussion reports that the Japanese LAM recipients had more favorable post-transplant survival than patients transplanted for other indications. The printed citing sentence does not make a claim about bilateral transplantation. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [304] Khawar, 2019, Clinical outcomes and survival following lung transplantation in patients with lymphangioleiomyomatosis, J Heart Lung Transplant source
- Not checked — no full text of the sourcecites [305] Baldi, 2017, Experience of lung transplantation in patients with lymphangioleiomyomatosis at a Brazilian reference centre, Lung source
- Not checked — no full text of the sourcecites [306] Kurosaki, 2020, Favorable survival even with high disease-specific complication rates in lymphangioleiomyomatosis after lung transplantation-long-term follow-up of a Japanese center, Clin Respir J source
- Not checked — no full text of the sourcecites [307] Kpodonu, 2005, The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis, J Heart Lung Transplant source
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“An updated version of the score, REVEAL 2.0, which incorporates estimated GFR and all-cause hospitalizations within the previous six-months, has emerged as a powerful predictor of mortality and clinical worsening.(285–287) Neither of the REVEAL scores has been validated prospectively.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > PULMONARY ARTERIAL HYPERTENSION (PAH)
What the sources say
- Not checked — no full text of the sourcecites [285] Benza, 2019, Predicting survival in patients with pulmonary arterial hypertension: The REVEAL Risk Score Calculator 2.0 and comparison with ESC/ERS-Based risk assessment strategies, Chest source
- Could not verifycites [286] Chakinala, 2018, Impact of declining renal function on outcomes in pulmonary arterial hypertension: a REVEAL registry analysis, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Discussion describes renal insufficiency as a mortality predictor included in the REVEAL risk score, and the Statistical analysis uses that score for adjustment. Our copy does not address REVEAL 2.0’s predictive performance or prospective validation (searched: REVEAL 2.0, clinical worsening, prospective validation). (LLM, conf=0.75)
- Not checked — no full text of the sourcecites [287] Frost, 2013, Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis, Chest source
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung volume reduction (LVR), performed by either surgical or bronchoscopic approach, is an option for a subset of COPD patients with advanced emphysema who meet strict selection criteria. These procedures have been associated with improved lung function, exercise capacity, and quality of life.(181–183)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
What the sources say
- Partly supportedcites [181] Criner, 2019, Improving lung function in severe heterogenous emphysema with the spiration valve system (EMPROVE). A multicenter, open-label randomized controlled clinical trial, Am J Respir Crit Care Med sourceExperimental — accuracy not yet measured
The Scientific Knowledge commentary says lung volume reduction surgery can improve lung function but is limited to eligible patients; the Results report improved lung function and health status after bronchoscopic valve treatment. The Results also say the improvement in exercise capacity was not statistically significant. The claim’s reference to delaying transplant is absent from the verbatim citing sentence and is not established by these passages. (LLM, conf=0.87)
- Partly supportedcites [182] Criner, 2018, A multicenter randomized controlled trial of Zephyr Endobronchial valve treatment in heterogeneous emphysema (LIBERATE), Am J Respir Crit Care Med sourceExperimental — accuracy not yet measured
The Introduction and Conclusion (pages not provided) describe surgical and bronchoscopic lung volume reduction as options for carefully selected patients with severe emphysema. The Discussion reports improvements in lung function, exercise capacity, and quality of life. The copy does not say these treatments delay transplantation; that point also does not appear in the verbatim citing sentence. (LLM, conf=0.85)
- Partly supportedcites [183] Fishman, 2003, A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema, N Engl J Med sourceExperimental — accuracy not yet measured
The Discussion (p. 2071) reports that lung-volume-reduction surgery increased the chance of improved exercise capacity, lung function, and quality of life, with benefits varying by patient subgroup. The Methods (page not supplied) describe surgical approaches, not bronchoscopic reduction, so this paper does not support the sentence’s extension to both approaches. The citing sentence does not make a transplant-delay claim; the Treatment section reports transplant counts but does not establish that surgery delayed transplantation. (LLM, conf=0.87)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The BODE index [BMI, airflow limitation (forced expiratory volume in one second), dyspnea and 6-min walk distance], which has been externally validated in at least 13 additional cohorts following the original derivation. The BODE index has been cited as the prognostic model of choice by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), and it formed the basis for listing recommendations in the 2014 ISHLT candidate selection guidelines. (4, 166–168)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
What the sources say
- Not checked — no full text of the sourcecites [4] Weill, 2015, A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant source
- Not checked — no full text of the sourcecites [166] Celli, 2004, The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease, N Engl J Med source
- Partly supportedcites [167] Bellou, 2019, Prognostic models for outcome prediction in patients with chronic obstructive pulmonary disease: systematic review and critical appraisal, BMJ sourceExperimental — accuracy not yet measured
The external validation studies section reports that BODE was externally validated in 13 cohorts. The Principal findings in context section says GOLD uses BODE in clinical decision-making for lung transplantation, but our copy does not say that BODE formed the basis of the 2014 ISHLT listing recommendations. (LLM, conf=0.88)
- Not matchedcites [168] Disease GIfCOL: Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2020 Report. 2020.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Active infections are generally contraindications for transplantation.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In cases of CF and non-CF bronchiectasis, the colonization of resistant bacteria progresses, thereby increasing mortality after surgery.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although COPD remains the most common indication for lung transplantation”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“transplantation is possible despite infections with non-tuberculous mycobacteria, non-aspergillus molds, and Burkholderia cepacia complex if accompanied by appropriate treatment [3,26-28].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the BODE score (body mass index, degree of airway obstruction, dyspnea, and exercise capacity score) is still the most important indicator, and along with it, FEV1 and the presence or absence of acute exacerbation determine whether transplantation is possible based on the presence or absence of evidence for pulmonary arterial hypertension (PAH), as summarized in Table 2 [3,42].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The current consensus is based on 2 tools for referral and listing: the REVEAL Registry 2.2 (Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management 2.0) and 2015 European Society of Cardiology/European Respiratory Society.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Group 2, with decreased left ventricular function, is not an indication for transplantation”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the World Symposium of Pulmonary Hypertension classification of PAH, group 1 is the most common indication.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“transplantation may be necessary if prostacyclin treatment is required for an appropriate intervention, there is accompanying liver or renal failure, or severe hemoptysis is present [3,59-62]”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In 2021, the International Society for Heart and Lung Transplantation (ISHLT) published a new consensus document for selecting candidates for lung transplantation [3].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“group 3 with PAH and accompanying pathological changes in the lung parenchyma can be considered for transplantation.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The use of immunosuppressive drugs after transplantation may lead to poor control of infection and progression to sepsis.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
Citations
Cites
Principles of Biomedical Ethics
(2012) · Thieves of Virtue · doi:10.7551/mitpress/9079.003.0009 · Cited by 13,453
Chen, Y., Wang, L., Kang, Q., Zhang, X., Yu, G., Wan, X., Wang, J., & Zhu, K. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000477308 · Cited by 10,730
Acute Respiratory Distress Syndrome
Ards Definition Task Force (2012) · JAMA · doi:10.1001/jama.2012.5669 · Cited by 9,066
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Celli, B. R., Cote, C. G., Marin, J. M., Casanova, C., Montes de Oca, M., Mendez, R. A., Pinto Plata, V., & Cabral, H. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa021322 · Cited by 4,015
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Haemodynamic definitions and updated clinical classification of pulmonary hypertension
Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M., Williams, P. G., & Souza, R. (2019) · European Respiratory Journal · doi:10.1183/13993003.01913-2018 · Cited by 3,813
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908681 · Cited by 2,403
A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030287 · Cited by 2,071 · cited 2×
“…benefit has been demonstrated in a select group of patients with upper lobe predominant emphysema and low exercise capacity who undergo surgical LVR. 183 184-187 Prior LVR surgery can lead to formation of pleural adhesions, which can pose technical challenges to the surgeon at the time of…”
Background
Research works printed but not linked: 1
- Kulig, 2017, Interpretation of workplace tests for cannabinoids, J Med Toxicol, 13, 106, 10.1007/s13181-016-0587-z · DOI · Paper page
Cited by
Sorted by citations
Items 501–600 of 798
Tetikkurt, C. (2024) · doi:10.69860/nobel.9786053359517 · Cited by 1
García-Pachón, E., & Padilla-Navas, I. (2024) · Cureus · doi:10.7759/cureus.72126 · Cited by 1
“The BODE index has been used as the prognostic model of choice for selecting candidates for lung transplantation in COPD patients; however, several studies have concluded that the BODE index overestimates mortality [18].”
Bronchoscopic Lung Volume Reduction
Franco‐Palacios, D. J., PRIEBE, R., Simanovski, J., Allenspach, L. L., Stagner, L. D., Waynick, L. K., Wang, Y., Lü, M., Desai, S., KAPADIA, D. V., et al. (2024) · CHEST Pulmonary · doi:10.1016/j.chpulm.2024.100117 · Cited by 1
Aguilar, P. M., Gómez-Carrera, L., Bonilla, G., Carpio, C., Zamarrón, E., Peña, M. F.-V., Díaz‐Almirón, M., Gayá, F., Villamañán, E., Sánchez, C. P., et al. (2024) · Atmosphere · doi:10.3390/atmos15121405 · Cited by 1
León-Román, F., Pintado-Cort, B., Barberà, J. A., Sellarés, J., Iturbe, D., López-Zubizarreta, M., Miguel, T. P., Durán, D., & Jiménez, D. (2025) · Open Respiratory Archives · doi:10.1016/j.opresp.2025.100406 · Cited by 2
Non-Tuberculous Mycobacteria in Lung Transplant Recipients – A Review
Kling, K., Mitchell, B. I., Stosor, V., Qi, C., Goldklang, E., & Zembower, T. (2025) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-025-00282-9 · Cited by 1
“AST, BTS, and ISHLT no longer consider M. abscessus to be contraindications to lung transplant but do recommend transplanting only at centers with mycobacteria experience [10, 31, 32].”
Die chirurgische Lungenvolumenreduktion – Alternative oder Ergänzung zur Lungentransplantation
Slama, A., & Aigner, C. (2025) · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · doi:10.1055/a-2576-6651 · Cited by 1
“Die Wahl des operativen Zugangs, das Ausmaß der Resektion und die uni-oder bilate-rale Vorgehensweise beeinflussen maßgeblich das funktionelle Ergebnis”
Kovacs, Z., Benazzo, A., & Jaksch, P. (2025) · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · doi:10.1055/a-2563-3691 · Cited by 1
“Eine engmaschige bildmorphologische Kontrolle, z.B. im Rahmen der 3-monatlichen LAS-Updates (LAS: Lung Allocation Score), ist je-doch empfehlenswert.”
Impact of lung resections on lung transplant grafts due to size discrepancy
Cuesta, V. M. M., Murillo-Brito, D. A., Argos-Vélez, P. J., et al. (2025) · Heart & Lung · doi:10.1016/j.hrtlng.2025.07.010 · Cited by 1
Impact of reference equations on lung function and outcomes in fibrotic interstitial lung disease
Marcoux, V. S., Mondal, P. K., Adegunsoye, A., et al. (2025) · ERJ Open Research · doi:10.1183/23120541.00055-2025 · Cited by 1
“In addition, FVC and D LCO are key considerations for eligibility of pharmaceutical drug trials and referral and listing of lung transplantation in patients with fibrotic ILD [3, 35 – 37].”
Renal Outcomes After Lung or Combined Heart‐Lung Transplantation in Pulmonary Hypertension
Hardy, L., D’Haenens, A., Belmans, A., Quarck, R. A., Aerts, G., Belge, C., Claessen, G., Kuypers, D. R. J., Vlieger, G. D., Verbelen, T., et al. (2025) · Pulmonary Circulation · doi:10.1002/pul2.70136 · Cited by 1
Zwintscher, N. P., de Perrot, M. E., Cypel, M., & Keshavjee, S. H. (2025) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2025.08.004 · Cited by 1
Self-citationRitter, A., Eagan, A. J., Levyn, H., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf550 · Cited by 1
Everolimus-Induced Pulmonary Toxicity in a Lung Transplant Recipient: A Case Report
Varón-Vega, F. A., Martínez-Ayala, M. C., Rodríguez, C., et al. (2025) · Cureus · doi:10.7759/cureus.95593 · Cited by 1
“Lung transplantation is a life-saving therapy for patients with advanced pulmonary diseases, but its long-term success is frequently limited by complications such as acute rejection, chronic graft dysfunction, and immunosuppressive drug toxicities [1,2].”
Multiresistant organisms: bacteria and beyond
Solé, A. (2022) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000976 · Cited by 1
Self-citationLatos, M., Urlik, M., Nęcki, M., Pawlak, D., Niepokój, K., Stącel, T., Zawadzki, F., Przybyłowski, P., & Ochman, M. (2022) · Transplantation Proceedings · doi:10.1016/j.transproceed.2022.02.041 · Cited by 1
Hage, R., & Schuurmans, M. M. (2022) · Transplantology · doi:10.3390/transplantology3030024 · Cited by 1
“Another important issue is that there is a general consensus described in the latest consensus document of the International Society of Heart and Lung Transplantation (ISHLT), that patients should be awake and able to discuss the lung transplantation and provide consent for the procedure [57,58].”
BackgroundAdding complexity to complexity: The role of concomitant cardiac surgery in lung transplantation
Scheinin, S. A., Singh, G., & Loebe, M. M. (2022) · Journal of Cardiac Surgery · doi:10.1111/jocs.16743 · Cited by 1
Pulmonary Hypertension Association's 2022 International Conference Scientific Sessions Overview
Alamri, A. K., Shelburne, N. J., Mayeux, J. D., & Brittain, E. L. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12182
“The ISHLT consensus suggested referral with increased risk score despite appropriate therapy, significant RV dysfunction, need for parenteral therapy, recent hospitalization for PAH, pulmonary veno‐occlusive disease and pulmonary capillary hemangiomatosis, signs of heart failure or secondary organ dysfunction, and lif…”
BackgroundTratamiento de la hipertensión pulmonar
Guerrero, M. A. S., Sánchez, E. H., & Gómez, J. L. Z. (2025) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2025.06.030 · Cited by 1
The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights from 2022
Martin, A. K., Feinman, J. W., Bhatt, H. V., Fritz, A. V., Subramani, S., Malhotra, A. K., Townsley, M. M., Sharma, A., Patel, S. J., Ha, B., et al. (2022) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2022.11.002 · Cited by 1
ERS Congress 2024: highlights from the Thoracic Surgery and Lung Transplantation Assembly
Esendagli, D. R., Mastromarino, M. G., Zúñiga, A. V., Migliore, M., & Meloni, F. (2025) · ERJ Open Research · doi:10.1183/23120541.01046-2024 · Cited by 2
“While the indications for lung transplantation remain largely consistent, the characteristics of recipients have significantly changed [13].”
Quantifying CLAD: A Promising Imaging-based Diagnostic Innovation
Halloran, K. M. (2021) · Transplantation · doi:10.1097/tp.0000000000003951
Narrative review of the evolution of lung transplant
Makdisi, G., & Cedeno-Rodriguez, A. (2021) · Current Challenges in Thoracic Surgery · doi:10.21037/ccts-21-11
The art of lung transplantation—lessons learnt from one thousand lung transplants
Sehgal, S., Mangukia, C. V., Toyoda, Y., et al. (2022) · Indian Journal of Thoracic and Cardiovascular Surgery · doi:10.1007/s12055-021-01314-x
“International consensus documents help guide when is the right time to refer and list; however, they don’t account for an individual patient circumstances, which only the treating physician is aware of [5].”
BackgroundPsychosocial Evaluation for Lung Transplantation: an Empirically Informed Update
Christon, L., & Smith, P. J. (2022) · Current Transplantation Reports · doi:10.1007/s40472-022-00360-7 · Cited by 1
Self-citationAktueller Stand der Transplantationsmedizin im Bereich Herz- und Lungentransplantation
Niehaus, H., Haverich, A., & Ius, F. (2022) · Zeitschrift für Herz- Thorax- und Gefäßchirurgie · doi:10.1007/s00398-022-00493-y
Latos, M., Nęcki, M., Urlik, M., Pawlak, D., Niepokój, K., Stącel, T., Zawadzki, F., Przybyłowski, P., & Ochman, M. (2022) · Transplantation Proceedings · doi:10.1016/j.transproceed.2022.02.059
Inpatient Management of the Acutely Decompensating Lung Transplant Candidate
Soder, S. A., Fontena, E., Salgado, J. C., Shahmohammadi, A., Samano, M. N., & Machuca, T. (2022) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2022.02.001
Successful lung transplant in a patient with a combined thrombophilia
Cuesta, V. M. M., Mena, S. T., & Fernandez, D. I. (2022) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2022.03.004
Editorial: Current opinion in organ transplantation: lung transplantation
Glanville, A. R. (2022) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000985
Self-citationLung Transplantation in Idiopathic Pulmonary Fibrosis
Goetz, R., Jain, N. K., Anjum, H., & Kaleekal, T. S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105725
Psychosocial Evaluation and Rehabilitation for Organ Transplant Recipients
Tsutsui, J., & Nishimura, K. (2022) · リハビリテーション医学 : 日本リハビリテーション医学会誌 · doi:10.2490/jjrmc.59.609
Indicaciones de trasplante pulmonar
Durán, D., Franquiz, W. B., Bobillo, J. R., & Oriol, A. J. (2022) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2022.09.013
Garza‐Castillon, R., & Bharat, A. (2022) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001203
Bystrova, S. G. (2022) · Russian Pediatric Journal · doi:10.46563/1560-9561-2022-25-5-350-356
Smith, K. S., Lee, S. A., Albers, B. K., et al. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.06.037
Quand penser à la transplantation pulmonaire ?
Ioakeim, F., Mazza, T., Casutt, A., Balmpouzis, Z., Lechartier, B., Krueger, T., Aubert, J., Berra, G., & Koutsokera, A. (2022) · JMIG · doi:10.53738/revmed.2022.18.804.2143
Avancées en transplantation pulmonaire
Mal, H. (2022) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(22)00774-1
“C’est d’ailleurs la position adoptée par les dernières recommandations de l’ISHLT (International Society for Heart and Lung Transplantation) qui mentionnent le cannabis comme une contre-indication relative [2].”
Recent Advances and Outcomes in Heart and Lung Transplantation
Kumar, A., Thite, S., Wazarkar, V., Ayyat, K. S., Gomez-Abraham, J., & Keshavamurthy, S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.109068
Lee, J. G. (2023) · The Korean Journal of Thoracic and Cardiovascular Surgery · doi:10.5090/jcs.22.159
“Although limited data exist, experts in the field recommend waiting at least 4–6 weeks after the onset of respiratory failure due to COVID19 prior to considering lung transplantation [4].”
BackgroundTransplantation pulmonaire pour pneumopathie interstitielle diffuse fibrosante
Mordant, P., Dauriat, G., Brugière, O., Borie, R., Crestani, B., & Reynaud‐Gaubert, M. (2023) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.12.012
Lung Cancer and Lung Transplantation
Jablonski, R. P. (2023) · Current Pulmonology Reports · doi:10.1007/s13665-023-00301-4
Transplantation pulmonaire pour hypertension pulmonaire sévère
Pavec, J. L., Savale, L., Prévôt, G., Montani, D., Sitbon, O., Fadel, É., Humbert, M. J. C., & Mercier, O. M. (2023) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.12.010
Préparation à la transplantation pulmonaire
Guen, M. L., Falque, L., & Pison, C. M. (2023) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.12.007 · Cited by 1
Dave, K., Sef, A. V., & Sef, D. (2023) · Shanghai Chest · doi:10.21037/shc-22-62
Transplantation pulmonaire et lymphangioléiomyomatose
Reynaud‐Gaubert, M., Pavec, J. L., & Uzunhan, Y. (2023) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2023.01.023
Impact of Sex and Age at Lung Transplantation on Long-Term Survival of Patients with Cystic Fibrosis
Razia, D., Omar, A., Grief, K., Walia, R., & Tokman, S. (2023) · OBM Transplantation · doi:10.21926/obm.transplant.2301176
Transplantation pulmonaire pour histiocytose langerhansienne pulmonaire
Brugière, O., Mercier, O., Lorillon, G., et al. (2023) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2023.01.022
Olson, M. T., Moin, A., Walia, T., et al. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-22-1817
“…consensus statements from the International Society for Heart and Lung Transplantation (4), these recommendations are actively being reconsidered (5) in lieu of an aging transplant waiting list as well as practice changes observed in a majority of larger centers, particularly over the last…”
A Breath of Fresh Air - Lung Transplantation Has Come of Age
Keshavamurthy, S., & Russell, C. (2023) · OBM Transplantation · doi:10.21926/obm.transplant.2302179
Early Postoperative Outcomes of Lung Transplant Recipients With Abdominal Adverse Events
Ramos, L. G., Cuesta, V. M. M., Fernandez, D. I., Tello-Mena, S., Sánchez-Moreno, L., Andia-Torrico, D., Alonso‐Lecue, P., Ballesteros-Sanz, M. Á., Naranjo-Gozalo, S., & Martínez, J. M. C. (2023) · Transplantation Proceedings · doi:10.1016/j.transproceed.2023.02.012
Acquired susceptivity phenotype: A target for precision
Gaffney, A. W., & Christiani, D. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00035-6
Özgür, G. K., Aydın, S. K., Mammadov, R., et al. (2023) · Transplantation Proceedings · doi:10.1016/j.transproceed.2023.03.035
Lung Transplantation for Hematopoietic Stem Cell Transplant Patients
Gadre, S. K., & Benninger, L. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-28797-8_23
José Gutiérrez, M., Víctor Pinochet, F., Paula Irazoqui, G., Guacolda Benavides, G., Christian Andrade, H., María de los Ángeles Orellana, F., & Joel Melo, T. (2022) · Revista chilena de enfermedades respiratorias · doi:10.4067/s0717-73482022000400226
Takada, J., Sato, M., Konoeda, C., Kaneko, H., Shimada, S., Hirata, Y., Yuasa, E., Oyanagi, T., Fukushima, H., & Nakajima, J. (2023) · General Thoracic and Cardiovascular Surgery Cases · doi:10.1186/s44215-023-00089-4
“Severe thoracic deformities such as scoliosis are considered relative contraindications to LTx [2, 3].”
BackgroundHighlights del 56° Congreso SEPAR
Sánchez-Salcedo, P., Llanos-González, A. B., Arenas, S. D., et al. (2023) · Open Respiratory Archives · doi:10.1016/j.opresp.2023.100265
Cardiothoracic Surgery and Nutrition
Patel, R., & Nixon, A. (2023) · Wiley eBooks · doi:10.1002/9781119809128.ch10
Multiorgan Transplantation: Heart–Lung
Barac, Y. D., Aravot, D., Shudo, Y., & Wallwork, J. L. (2023) · doi:10.1002/9781119633884.ch29
The Acute Lung Failure Patient and Temporary Mechanical Support
Shah, P., Creel-Bulos, M. C., & Chandrashekaran, S. (2023) · doi:10.1002/9781119633884.ch76
Prioritization: Candidate Selection and Organ Allocation Systems
Holm, A. M., & Hartwig, M. G. (2023) · doi:10.1002/9781119633884.ch79
Self-citationTechnical Considerations in the Complex Recipient
Borgi, J. F., & Forest, S. (2023) · doi:10.1002/9781119633884.ch87
Going the distance: predictors of multi-decade survival following lung transplantation
Rucker, A. J., & Hartwig, M. G. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-2023-09
“However, consensus guidelines from the International Society for Heart and LTx caution for careful selection of transplant candidates over age 65 (13).”
Self-citationBertani, A., Tancredi, G., Monte, L. D., et al. (2023) · Organ and tissue transplantation · doi:10.1007/978-3-319-20788-9_12-1
Lung Allocation Score Exceptions in Persons with Cystic Fibrosis Undergoing Lung Transplant
Bayomy, O. F., Bradford, M. C., Milinic, T., Kapnadak, S. G., Morrell, E. D., Lease, E. D., Goss, C. H., & Ramos, K. J. (2023) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202306-509oc
Self-citationPrognosis factors in heart-lung transplantation: 30 years experience in a reference center
Ochoa, C. O., Navarro, J. C., Ávila, O. S., et al. (2023) · Cirugía Española (English Edition) · doi:10.1016/j.cireng.2023.08.004
Lung Transplantation for Pulmonary Artery Hypertension
Sunder, T., Thangaraj, P. R., Kuppusamy, M. K., Sriraman, K. B., Selvi, C., & Kumar, S. Y. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002961
Manali, E. D., Griese, M., & Papiris, S. A. (2023) · ERJ Open Research · doi:10.1183/23120541.00646-2023
“Indeed, in idiopathic pulmonary fibrosis (IPF), which represents worldwide the most common indication for LTx, the median post-transplant survival reported is 5.2 years for IPF and 6.7 years for other fibrotic ILDs [17, 18].”
BackgroundInfluentialReply: Disparities in Lung Transplantation: Metrics Matter
Brems, J. H., Balasubramanian, A., & McCormack, M. C. (2023) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202310-920le
“…context of lung transplant, a shift in reference equations (and thus in percent predicted spirometry values) will impact which patients meet International Society for Heart and Lung Transplantation guideline criteria for referral or listing for transplant across a range of respiratory diseases (6).”
BackgroundTomioka, Y., Otani, S., Tanaka, S., et al. (2023) · Transplantation Direct · doi:10.1097/txd.0000000000001556
Mulheres após Transplante de Órgãos Sólidos: Um Olhar Sobre a Saúde Ginecológica
Juliato, C. R. T., Guida, J. P. D. S., & Surita, F. G. (2023) · Brazilian Journal of Transplantation · doi:10.53855/bjt.v26i1.544_port
Ochoa, C. O., Navarro, J. C., Ávila, O. S., et al. (2023) · Cirugía Española · doi:10.1016/j.ciresp.2023.08.002
Neumotórax espontáneo ocasionado por linfangioleiomiomatosis
Tinney, N., Castillo, J., Camacho, I., & Meneses, G. (2023) · Boletín de la Sociedad Peruana de Medicina Interna/Revista de la Sociedad Peruana de Medicina Interna · doi:10.36393/spmi.v36i4.785
Yaqoob, M., DeCato, T. W., & Oudiz, R. J. (2024) · Current Respiratory Medicine Reviews · doi:10.2174/011573398x268093231226043639
Tan, C., & Wang, J. (2024) · Journal of Biobased Materials and Bioenergy · doi:10.1166/jbmb.2024.2357
How Old Is Too Old? Bridging the Gap in Lung Transplant Outcomes
Endo, T., & Fox, M. P. (2024) · ASAIO Journal · doi:10.1097/mat.0000000000002165
Pulmonary Rehabilitation in Patients with Lung Transplantation
Kim, S. H. (2023) · Annals of CardioPulmonary Rehabilitation · doi:10.53476/acpr.2023.3.2.42
Repeated Single-lung Transplantation After Previous Contralateral Pneumonectomy—A Unique Challenge
Ohm, B., Kalbhenn, J., Hettich, I. M., et al. (2024) · Transplantation Direct · doi:10.1097/txd.0000000000001613
Woo, W., Kim, H. S., Bharat, A., et al. (2024) · medRxiv · doi:10.1101/2024.03.14.24304302
“The 2021 ISHLT consensus has begun to acknowledge the potential eligibility of patients with pre-transplant malignancy (Pre-TM) for transplantation 8 , although the lack of robust evidence supporting these guidelines underscores ongoing uncertainty.”
BackgroundAhmed, S. U., & Schaheen, L. W. (2024) · Contemporary surgical clerkships · doi:10.1007/978-3-031-44645-0_26
Interventionelle und operative Therapien
Schellenberg, M., den Winkel, J. O., & Gompelmann, D. (2024) · Fachwissen Pflege · doi:10.1007/978-3-662-67237-2_9
Iatrogenic esophageal dysmotility as a barrier to transplantation in pulmonary arterial hypertension
Miller, M. S., Johnson, S. W., Opotowsky, A. R., Landzberg, M. J., Sharma, N., Goldberg, H. J., Wong, A. K., Witkin, A. S., Rodriguez‐Lopez, J., Goldstein, R. H., et al. (2024) · JHLT Open · doi:10.1016/j.jhlto.2024.100098
Lung Transplantation as a treatment strategy for Pulmonary Emphysema
Cornea, A. L., Linnane, S. J., Riddell, P., et al. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004832
Lung transplantation: practical and important directions of care
Glanville, A. R., & Lehr, C. J. (2024) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001081
Self-citationWagner, L. E., Rosa, G. H., Plachi, F., da Silva, A. B., Imperador, A. D. S., de Azevedo, A. C., Gazzana, M. B., Neder, J. A., & Berton, D. C. (2024) · Respiratory Care · doi:10.4187/respcare.11751 · Cited by 1
“27 Participants with advanced COPD, ILD, and pulmonary arterial hypertension are more likely to desaturate than those with other diagnoses, 20-22 and the magnitude of desaturation is greatest in ILD and COPD.”
Recent Advances in Chronic Obstructive Pulmonary Disease
Getahun, B., Bekel, A. A., Demeke, D., Gebeye, M. D., Zemene, D., & Beyene, E. L. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1003820
Transplantation-Related Lung Pathology
Schulte, J. J., & Husain, A. N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-93548-7.00023-4
Kwiatka, P., Kwapisz, K., Sokołowski, R., et al. (2024) · Annals of Agricultural and Environmental Medicine · doi:10.26444/aaem/189777
Transplantation : une discipline fondée sur l’épreuve
Sandot, A., Merveilleux, C., Pradier, H. M., & Pradère, P. (2024) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(24)00014-4
Appiani, F., Abara, B., Ramirez, I., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4895876
Reviews Evidence-Based Approach to Treatment and Prevention of Bronchiectasis
Rajagopala, S. (2024) · Current Pulmonology Reports · doi:10.1007/s13665-024-00358-9
“Recurrent hemoptysis not amenable to these interventions, especially when mas - sive, is an indication for referral to lung transplantation [42]. with a slower response-time and is an alternative in those at-risk or have developed complications due to steroids [ 35].”
Pediatric Lung Transplantation for Pulmonary Vascular Diseases
Mıdyat, L., Muise, E. D., & Visner, G. A. (2024) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2024.02.023
Reply to Miller: Race-Specific Interpretation of Spirometry
Brems, J. H., Balasubramanian, A., & McCormack, M. C. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202406-610le
Plunkett, D., Eaton, D. A., Brown, R., et al. (2024) · Physiotherapy Practice and Research · doi:10.3233/ppr-240876
“This highlights the potential need for specific education around expectations or clinical psychology input during the assessment phase to help to manage patient expectations and support them through this process as has been incorporated into lung transplant assessment [21].”
Cryobiopsy as a Diagnostic Tool in Lung Transplantation: A Case Report
García-Rueda, J. E., Botero-Bahamón, J. D., Palacio, A. C., et al. (2024) · Cureus · doi:10.7759/cureus.68554
“Lung transplantation is an option for patients with advanced lung pathologies whose survival is expected to be less than 50% in the next two years [1].”
BackgroundMoll, M. R., Pratte, K., Debban, C. L., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-71714-7
Dealing with Difficult Bugs Before Lung Transplantation
Mehta, N., Lyon, G. M., & Pouch, S. M. (2024) · Organ and tissue transplantation · doi:10.1007/978-3-319-20788-9_16-1
Landoas, A., Chapuis, R., Briault, A., et al. (2024) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2024.09.010
Metadata
- Authors
- Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., Hartwig, M. G., Kapnadak, S. G., Kolaitis, N. A., Kotloff, R. M., Patterson, C. M., Shlobin, O. A., Smith, P. J., Solé, A., Solomon, M., Weill, D., Wijsenbeek, M. S., Willemse, B. W. M., Arcasoy, S. M., & Ramos, K. J.
- Affiliations
- University of California, San Francisco (US)
- Oslo University Hospital (NO)
- Cleveland Clinic (US)
- St Vincent's Hospital Sydney (AU)
- Krishna Institute of Medical Sciences (IN)
- University of Toronto (CA)
- Medical University of South Carolina (US)
- Sahlgrenska University Hospital (SE)
- Duke University (US)
- University of Washington (US)
- University of Pennsylvania (US)
- Royal Papworth Hospital (GB)
- Inova Fairfax Hospital (US)
- Erasmus MC (NL)
- University Medical Center Groningen (NL)
- Columbia University (US)
- Corresponding author
- Leard, Lorriana E.
- ORCID
- Leard, Lorriana E.
- Holm, Are M.
- Valapour, Maryam
- Glanville, Allan R.
- Attawar, Sandeep
- Aversa, Meghan
- Christon, Lillian M.
- Cypel, Marcelo
- Dellgren, Göran
- Hartwig, Matthew G.
- Kapnadak, Siddhartha G.
- Kolaitis, Nicholas A.
- Patterson, Caroline M.
- Shlobin, Oksana A.
- Smith, Patrick J.
- Solomon, Melinda
- Wijsenbeek, Marlies S.
- Willemse, Brigitte W.M.
- Arcasoy, Selim M.
- Ramos, Kathleen J.
- Venue
- The Journal of Heart and Lung Transplantation
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 40
- Issue
- 11
- Pages
- 1349-1379
- ISSN
- 1053-2498 (ISSN-L)
- PMC
- PMC8979471
- OpenAlex
- W3183806681
- Semantic Scholar
- 428c0f28db10a88c62c6b907d2c92a02bac6b503
- Cited by
- 821
- References
- 363
- Citations by year
- 2026: 170 · 2025: 181 · 2024: 186 · 2023: 176 · 2022: 97 · 2021: 11
- FWCI
- 110.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Heart and Lung Transplantation (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- U.S. Department of Health and Human Services
- Cystic Fibrosis Foundation
- Boomer Esiason Foundation
- Bristol-Myers Squibb
- United Therapeutics Corporation
- European Respiratory Society
- Vertex Pharmaceuticals
- Savara Pharmaceuticals
- Galecto
- ZonMw
- Astellas Pharma
- Lung Foundation Netherlands
- National Institutes of Health
- Health Resources and Services Administration
- National Heart, Lung, and Blood Institute (K23HL138154)
- Topics
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Organ Donation and Transplantation
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- lung transplantation, transplant candidate selection, advanced lung disease, referral timing, transplant evaluation, transplant listing, transplant ethics, risk stratification, International Society for Heart and Lung Transplantation
- MeSH terms
- Contraindications, Cystic Fibrosis, Humans, Societies, Medical, Lung Transplantation, Patient Selection, Pulmonary Disease, Chronic Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-25 (prompt extract-v2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
